DIFGEN PHARMS
GenericsDIFGEN PHARMS is a generic drug manufacturer focused on Cardiovascular.
DIFGEN PHARMS's Key Drugs
DIFGEN PHARMS's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
DIFGEN PHARMS's Recent FDA Approvals
New NDA/BLA approvals for DIFGEN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
DIFGEN PHARMS's Therapeutic Areas
DIFGEN PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DIFGEN PHARMS's Top Competitors
DIFGEN PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DIFGEN PHARMS Pipeline Snapshot
Active clinical trials for DIFGEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1997-10-20
- Latest
- 2026-08-14
- Applications
- 6